ZE77-0273
/ Eilean Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 13, 2025
A Novel, wild-type sparing pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC
(AACR-NCI-EORTC 2025)
- "Conclusions ZE77-0273 is a promising, AI-designed, reversible pan-EGFR inhibitor with broad activity across classical, atypical, and resistance EGFR mutations. Its favorable PK profile, preclinical efficacy, and broad mutational coverage support its advancement toward clinical development in EGFR-mutant NSCLC."
Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
October 13, 2025
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(PRNewswire)
Preclinical • Non Small Cell Lung Cancer
1 to 2
Of
2
Go to page
1